Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001379017 | SCV001576732 | likely pathogenic | Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant | 2020-08-14 | criteria provided, single submitter | clinical testing | This variant is an in-frame deletion of the genomic region encompassing exon(s) 2-8 of the FLNC gene. It preserves the integrity of the reading frame. This variant has not been reported in the literature in individuals with FLNC-related conditions. This variant disrupts the p.Ala193 amino acid residue in FLNC. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 21620354, 30734317, 2781633). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |